



Biomarkers for the Early Detection and Treatment of Cancers

Guest Editors:

Prof. Dr. Barbara Mroczo

Department of
Neurodegeneration Diagnostics,
Medical University of Białystok,
15-269 Białystok, Poland

**Dr. Monika Gudowska-
Sawczuk**

Department of Biochemical
Diagnostics, Medical University of
Białystok, Waszyngtona 15A St.,
15-269 Białystok, Poland

Deadline for manuscript
submissions:

closed (30 June 2024)

Message from the Guest Editors

The number of cancer cases is increasing every year. Prostate cancer is the most common cancer among men and breast cancer is the most common among women. However, a worrying phenomenon is the very large increase in the incidence of other types of cancer, including colorectal cancer and cancers of the urinary system. In developed countries, they are the second leading cause of death after cardiovascular diseases.

Rapidly developing cancer does not necessarily mean that the patient's prognosis is poor. Many of these cancers can be successfully treated. There is, however, a group of cancers that do not necessarily grow faster, but are detected late, only after metastasis. Cancers that are detected early and properly treated do not have to be a judgment against which there is no appeal. Taking into account above, this Special Issue aims to highlight new findings regarding biomarkers that could improve the early detection of cancer patients and assess their potential clinical application in the rapid diagnosis in early stages of developing disease. Tumor markers can be used in screening for early detection of cancer or during treatment to monitor its effectiveness and staging cancer.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)